📊 PGEN Key Takeaways
Is Precigen, Inc.. (PGEN) a Good Investment?
Despite impressive 146.7% revenue growth, PGEN faces critical financial distress with unsustainable cash burn (-$44.1M FCF), severe leverage (4.62x debt-to-equity ratio), and negative interest coverage (-0.5x) indicating inability to service debt from operations. At current burn rate, the company's $7.5M cash position provides less than 1 month of runway, creating immediate solvency risk.
Precigen, Inc.. Key Strengths (PGEN)
- Strong revenue growth of 146.7% YoY demonstrates market traction
- Excellent liquidity ratios (4.82x current ratio, 4.76x quick ratio) provide near-term payment capacity
- Operates in high-growth pharmaceutical sector with innovation potential
PGEN Stock Risks: Precigen, Inc.. Investment Risks
- Catastrophic cash burn of -$43.8M operating cash flow with only $7.5M cash on hand
- Dangerously high leverage (4.62x debt-to-equity, $93.5M long-term debt vs $20.2M equity) with negative interest coverage of -0.5x
- Deteriorating profitability despite revenue growth: net income down 240.4% YoY with -34.1% net margin and -25.8% operating margin, indicating business model is unprofitable at scale
Key Metrics to Watch
- Operating cash flow and cash runway (critical near-term survival metric)
- Path to EBITDA/operating profitability and timeline
- Debt refinancing ability and maturity schedule of $93.5M long-term debt
Precigen, Inc.. (PGEN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.82x current ratio provides a solid financial cushion.
PGEN Profit Margin, ROE & Profitability Analysis
PGEN vs Healthcare Sector: How Precigen, Inc.. Compares
How Precigen, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Precigen, Inc.. Stock Overvalued? PGEN Valuation Analysis 2026
Based on fundamental analysis, Precigen, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Precigen, Inc.. Balance Sheet: PGEN Debt, Cash & Liquidity
PGEN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Precigen, Inc..'s revenue has declined by 96% over the 5-year period, indicating business contraction. The most recent EPS of $-0.39 indicates the company is currently unprofitable.
PGEN Revenue Growth, EPS Growth & YoY Performance
PGEN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.3M | -$7.9M | $-0.02 |
| Q2 2023 | $1.8M | -$17.6M | $-0.08 |
| Q1 2023 | $1.9M | -$19.3M | $-0.10 |
| Q3 2022 | $3.3M | -$29.8M | $-0.15 |
| Q2 2022 | $2.9M | -$17.6M | $-0.09 |
| Q1 2022 | $24.5M | -$17.3M | $-0.09 |
| Q3 2021 | $21.6M | -$29.5M | $-0.15 |
| Q2 2021 | $30.4M | -$20.1M | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Precigen, Inc.. Dividends, Buybacks & Capital Allocation
PGEN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Precigen, Inc.. (CIK: 0001356090)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PGEN
What is the AI rating for PGEN?
Precigen, Inc.. (PGEN) has an AI grade of D with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PGEN's key strengths?
Claude: Strong revenue growth of 146.7% YoY demonstrates market traction. Excellent liquidity ratios (4.82x current ratio, 4.76x quick ratio) provide near-term payment capacity.
What are the risks of investing in PGEN?
Claude: Catastrophic cash burn of -$43.8M operating cash flow with only $7.5M cash on hand. Dangerously high leverage (4.62x debt-to-equity, $93.5M long-term debt vs $20.2M equity) with negative interest coverage of -0.5x.
What is PGEN's revenue and growth?
Precigen, Inc.. reported revenue of $23.3M.
Does PGEN pay dividends?
Precigen, Inc.. does not currently pay dividends.
Where can I find PGEN SEC filings?
Official SEC filings for Precigen, Inc.. (CIK: 0001356090) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PGEN's EPS?
Precigen, Inc.. has a diluted EPS of $-0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PGEN's fundamental grade?
Based on our AI fundamental analysis in May 2026, Precigen, Inc.. has a D grade with 85% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PGEN stock overvalued or undervalued?
Valuation metrics for PGEN: ROE of -39.2% (sector avg: 15%), net margin of -34.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PGEN's AI grade for 2026?
Our dual AI analysis gives Precigen, Inc.. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PGEN's free cash flow?
Precigen, Inc..'s operating cash flow is $-43.8M, with capital expenditures of $258.0K. FCF margin is -189.6%.
How does PGEN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -34.1% (avg: 12%), ROE -39.2% (avg: 15%), current ratio 4.82 (avg: 2).
Is Precigen, Inc.. carrying too much debt?
PGEN has a debt-to-equity ratio of 4.62x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 4.82 suggests adequate short-term liquidity.